| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
CP-547632 TFA manufacturers
- CP-547632 TFA
-
- $3400.00
-
2026-07-27
- CAS:2805804-54-8
- Purity:
- Supply Ability: 10g
|
| | CP-547632 TFA Basic information |
| Product Name: | CP-547632 TFA | | Synonyms: | CP-547632 TFA;4-Isothiazolecarboxamide, 3-[(4-bromo-2,6-difluorophenyl)methoxy]-5-[[[[4-(1-pyrrolidinyl)butyl]amino]carbonyl]amino]-, 2,2,2-trifluoroacetate (1:1) | | CAS: | 2805804-54-8 | | MF: | C20H24BrF2N5O3S.C2HF3O2 | | MW: | 646.43 | | EINECS: | | | Product Categories: | | | Mol File: | 2805804-54-8.mol |  |
| | CP-547632 TFA Chemical Properties |
| form | Solid | | color | Off-white to light yellow |
| | CP-547632 TFA Usage And Synthesis |
| Uses | CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy[1]. | | in vivo | CP-547632 TFA (p.o.; 6.25-100 mg/kg/day; for 10-24 days) causes a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts[1].
CP-547632 TFA (oral; 50 mg/kg; a single oral dose) yieldes plasma concentrations above 500 ng/ml for 12 hours[1].
| Animal Model: | Athymic female mice (CD-1 nu/nu) bearing tumors (75-150 mm in size)[1] | | Dosage: | 6.25, 12.5, 25, 50, 100 mg/kg | | Administration: | PO; daily; 10-24 days | | Result: | Caused a dose-dependent inhibition of growth in Colo-205, DLD-1, and MDA-MB-231 xenografts.
|
| Animal Model: | Female athymic mice bearing H-Ras tumor[1] | | Dosage: | 50 mg/kg | | Administration: | Oral | | Result: | A single oral dose of 50 mg/kg yielded plasma concentrations above 500 ng/ml for 12 hours.
|
| | IC 50 | VEGFR2: 11 nM (IC50); FGFR: 9 nM (IC50) | | References | [1] Beebe JS, et al. Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003 Nov 1;63(21):7301-9. PMID:14612527 |
| | CP-547632 TFA Preparation Products And Raw materials |
|